Browse studies

Find your next paid study

172 recruiting studies matching your filters

AN INTERVENTIONAL, OPEN-LABEL, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY OR IN COMBINATION IN ADULT PARTICIPANTS WITH EARLY-STAGE RESECTABLE OR LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER

This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with c…

CarcinomaNon-Small-Cell LungLung Cancer (NSCLC)+6 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

PfizerNCT07489066

Phase 1

First-in-Human, Phase 1 Study of PHN-012, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel an…

Colon CancerPancreatic CancerLung Cancer (NSCLC)+2 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Pheon TherapeuticsNCT07127874

Phase 2

A Double-Blind Phase II Randomized Study of Adaptively Delivered LINAC-Based Stereotactic Radiation for Volatile Brain Metastases With Same-Day Planning and Margin Reduction

The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval …

Brain Metastases, AdultBrain Tumor - MetastaticBrain Metastases From Non-small Cell Lung Cancer (NSCLC)+1 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Ayal A. Aizer, MDNCT07132190

Phase 1

A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants With Advanced Solid Tumors

The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum admini…

Advanced Solid TumorsNSCLC AdenocarcinomaCholangiocarcinoma+2 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

MacroGenicsNCT06723236

Phase 1

A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignan…

High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)Non-small Cell Lung Cancer (NSCLC)

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Bristol-Myers SquibbNCT06476808

Phase 1

A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with adva…

Head and Neck CarcinomaAdenoid Cystic CarcinomaLung Cancer+22 more

Estimated

~$150 – $4,200

Observational

PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study

This study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage II-III primary l…

NSCLC Stage IINSCLC, Stage III

Estimated

~$10 – $750

Actual pay is set by the research site.

University of UtahNCT06945484

Phase 2

Assessing the Impact of Circadian Rhythm on Anti-PD-1/PD-L1 Immunotherapy

This study aims to determine whether morning versus afternoon treatment impacts efficacy of (standard of care) immunotherapy in a broad patient population. Pat…

Advanced/Metastatic NSCLC

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Liza Villaruz, MDNCT07224971

Quality Improvement Study of a New Generation of Whole Body PET Scanners

The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn …

Non Small Cell Lung Carcinoma NSCLCHead and Neck CancerProstate Cancer

Estimated

~$10 – $750

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07690917

Phase 2

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non…

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Taiho Oncology, Inc.NCT05967689

Phase 3

A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs gr…

IO-resistant sqNSCLC

Estimated

~$50 – $2,250

Actual pay is set by the research site.

TakedaNCT07217301

Phase 1

A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of…

OncologyMEK MutationRAF Gene Mutation+6 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Nested Therapeutics, IncNCT06326411